Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-03-07
2006-03-07
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S148100, C424S160100, C424S188100, C424S208100, C530S387900, C530S388350, C530S389400
Reexamination Certificate
active
07008622
ABSTRACT:
A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.
REFERENCES:
patent: 4871488 (1989-10-01), Mannino
patent: 5019510 (1991-05-01), Wain-Hobson
patent: 5110802 (1992-05-01), Cantin
patent: 5158877 (1992-10-01), Edwards
patent: 5238822 (1993-08-01), Dykes
patent: 5597895 (1997-01-01), Gaynor
patent: 5606026 (1997-02-01), Rodman
patent: 5674980 (1997-10-01), Frankel
patent: 5891994 (1999-04-01), Goldstein
patent: 6193981 (2001-02-01), Goldstein
patent: 6399067 (2002-06-01), Goldstein
patent: 6524582 (2003-02-01), Goldstein
patent: 6525179 (2003-02-01), Goldstein
patent: 2003/0166832 (2003-09-01), Goldstein
patent: 2003/0180326 (2003-09-01), Goldstein
patent: WO87/02989 (1987-05-01), None
patent: WO91/09958 (1991-07-01), None
patent: WO91/10453 (1991-07-01), None
patent: WO92/07871 (1992-05-01), None
patent: WO92/14755 (1992-09-01), None
patent: WO95/31999 (1995-11-01), None
patent: WO99/02185 (1999-01-01), None
G. Zauli et al., “An Autocrine Loop of HIV Type-1 Tat Protein Responsible for the Improved Survival/Proliferation Capacity of Permanently Tat-Transfected Cells and Required for Optimal HIV-1 LTR Transactivating Activity”, J. Acq. Imm. Def. Synd. Hum. Retrovirol., 10(3):306-316 (Nov. 1, 1995).
Webster's Ninth New Collegiate Dictionary, p. 602 (1990).
D. McPhee et al, “Recognition of Envelope and tat Protein Synthetic Peptide Analogs by HIV Positive Sera or Plasma”, FEBS Letters, 233(2):393-396 (Jun., 1988).
C. Li et al, “Tat Protein Induces Self-Perpetuating Permissivity for Productive HIV-1 Infection”, Proc. Natl. Acad. Sci. USA, 94:8116-8120 (Jul., 1997).
D. Brake et al, “Characterization of Murine Monoclonal Antibodies to the tat Protein from Human Immunodeficiency Virus Type 1”, J. Virol., 64:962-965 (Feb., 1990).
Harlow et al, Antibodies, a Laboratory Manual, pp. 96-97 (1988).
J. Hinkula et al, “Recognition of Prominent Viral Epitopes Induced by Immunization with Human Immunodeficiency Virus Type 1 Regulatory Genes”, J. Virol., 71(7):5528-5539 (Jul., 1997).
G. Pilkington et al, “Recombinant Human Fab Antibody Fragments to HIV-1 REV and TAT Regulatory Proteins: Direct Selection from a Combinatorial Phage Display Library”, Mol. Immunol., 33(4/5):439-450 (1996).
M. Sande et al, “Antiretroviral Therapy for Adult HIV-Infected Patients”, JAMA, 270(12):2583-2589 (Dec. 1, 1993).
M. Seligmann et al, “Concorde: MRC/ANRS Randomised Double-Blind Controlled Trial of Immediate and Deferred Zidovudine in Symptom-free HIV Infection”, Lancet, 343:871-881 (Apr. 9, 1994).
L. Steinaa et al, “Antibody to HIV-1 Tat Protein Inhibits the Replication of Virus in Culture”, Arch. Virol., 139:263-271 (1994).
K. Suzue et al, “Adjuvant-Free hsp70 Fusion Protein System Elicits Humoral and Cellular Immune Responses to HIV-1 p24”, J. Immunol., 156:873-879 (Jan. 15, 1996).
J. Tam, “Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System”, Proc. Natl. Acad. Sci. USA, 85:5409-5413 (Aug., 1988).
B. Tindall et al, “Primary HIV Infection: Host Responses and Intervention Strategies”, AIDS, 5(1):1-14 (Jan., 1991).
S. Welles et al, “Prognostic Value of Plasma Human Immunodeficiency Virus Type 1(HIV-1) RNA Levels in Patients with Advanced HIV-1 Disease and with Little or No Prior Zidovudine Therap”, J. Infect. Dis., 174:696-703 (Oct., 1996).
S. Wolinsky et al, “Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection”, Science, 272:537-542 (Apr. 26, 1996).
A. Meyerhans et al, “Temporal Fluctuations in HIV Quasispecies in vivo are not Reflected by Sequential HIV Isolations”, Cell, 58:901-910 (Sep. 8, 1989).
J. Osborn, “The Rocky Road to an AIDS Vaccine”, J. Acq. Imm. Def. Syndr. Hum. Retrovirol., 9(1):26-29 (May, 1995).
W. Paul, “Can the Immune Response Control HIV Infection?”, Cell, 82:177-182 (Jul. 28, 1995).
B. Preston et al, “Fidelity of HIV-1 Reverse Transcriptase”, Science, 242:1168-1171 (Nov. 25, 1988).
M. Re et al, “Effect of Antibody to HIV-1 Tat Protein on Viral Replication in Vitro and Progression of HIV-1 Disease in Vivo”, J. Acq. Imm. Def. Synd. Hum. Retroviral., 10(4):408-416 (Dec. 1, 1995).
J. Roberts et al, “The Accuracy of Reverse Transcriptase from HIV-1”, Science, 242:1171-1173 (Nov. 25, 1988).
M. Saag et al, “Hiv Viral Load Markers in Clinical Pratice”, Nature Medicine, 2(6):625-629 (Jun., 1996).
M. Saag et al, “A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase”, N. Engl. J. Med., 329(15):1065-1072 (Oct. 7, 1993).
K. Saksela et al, “Human Immunodeficiency Virus Type 1 mRNA Expression in Peripheral Blood Cells Predicts Disease Progression Independently of the Numbers of CD4+ Lymphocytes”, Proc. Natl. Acad. Sci. USA, 91:1104-1108 (Feb., 1994).
G. Goldstein, “HIV-1 Tat Protein is a Potential AIDS Vaccine”, Nature Medicine, 2(9):960-964 (Sep., 1996).
B. Haynes, “Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development”, Science, 260:1279-1286 (May 28, 1993).
W. Krone et al, “Natural Antibodies to HIV-tat Epitopes and Expression of HIV-1 Genes in Vivo”, J. Med. Virol., 26:261-270 (Nov., 1988).
K. Kusumi et la, “Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity in vivo and after Cocultivation in vitro”, J. Virol., 66(2):875-885 (Feb., 1992).
B. Larder et al, “HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy”, Science, 243:1731-1733 (Mar. 31, 1989).
T-H. Lee et al, “Circulating HIV-1-Infected Cell Burden from Seroconversion to AIDS: Importance of Postseroconversion Viral Load on Disease Course”, J. Acq. Imm. Def. Synd., 7(4):381-388 (Apr., 1994).
N. Letvin, “Vaccines Against Human Immunodeficiency Virus—Progress and Prospects”, N. Engl. J. Med., 329(19):1400-1405 (Nov. 4, 1993).
D. Mann et al, “Endocytosis and Targeting of Exogenous HIV-1 Tat Protein”, EMBO J., 10(7):1733-1739 (Jul., 1991).
J. Mellors et al, “Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma”, Science, 272:1167-1170 (May 24, 1996).
A. Aldovini et al, “Synthesis of the Complete Trans-Activation Gene Product of Human T-Lymphotropic Virus Type III inEscherichia coli: Demonstration of Immunogenicity in vivo and Expression in vitro”, Proc. Natl. Acad. Sci. USA, 83:6672-6676 (Sep., 1986).
C. Baumberger et al, “High Levels of Circulating RNA in Patients with Symptomatic HIV-1 Infection”, AIDS, 7(Suppl. 2):S59-S64 (Nov., 1993).
M. Clerici et al, “T-Cell Proliferation to Subinfectious SIV Correlates with Lack of Infection after Challenge of Macaques”, AIDS, 8(10):1391-1395 (Oct., 1994).
R. Coombs et al, “Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level with Risk of Clinical Progression in Patients with Advanced Infection”, J. Infect. Dis., 174:704-712 (Oct., 1996).
M. Daniel et al, “Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in th
Housel James
Howson and Howson
Parkin Jeffrey S.
Thymon L.L.C.
LandOfFree
Methods and compositions for impairing multiplication of HIV-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for impairing multiplication of HIV-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for impairing multiplication of HIV-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554593